The world's first bivalent mRNA vaccine candidate against respiratory syncytial virus, or RSV, kicked off Phase I clinical ...

Infants are among the most susceptible to respiratory complications from respiratory syncytial virus, or RSV. While they can ...

Current guidelines recommend that pregnant people receive a vaccine against respiratory syncytial virus (RSV) -- which typically causes mild, cold-like symptoms in most adults but can be deadly for ...

Regarding hospitalizations among immunocompetent older adults, vaccine effectiveness was 83% for the GSK vaccine and 73% for ...

The CDC recommends a single dose of any FDA-approved respiratory syncytial virus (RSV) vaccine for all adults ages 75 years ...

(Reuters) -Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in ...

Moderna reported a surprising third-quarter profit on Thursday, driven by cost reductions and stronger-than-expected sales of ...

after a weaker-than-expected performance for its respiratory syncytial virus (RSV) and shingles vaccines in the third quarter, pushing shares down as much as 4.1%. The British drugmaker now ...

The North Bay Parry Sound District Health Unit announced the availability of a new preventive medication for Respiratory Syncytial Virus for newborns and eligible infants up to 24 months of age. The ...

The North Bay Parry Sound District Health Unit announced the availability of a new preventive medication for Respiratory Syncytial Virus for newborns and eligible infants up to 24 months of age.

Respiratory virus data included in the interactive data application is up-to-date as of November 2, 2024. Among its new features, the dashboard now includes RSV Severe Outcomes data.